$8.800
-0.281 (-3.19%)終値時点
- High
- 9.490
- Open
- 8.820
- VWAP
- 8.90
- Vol
- 349.99K
- Mkt Cap
- —
- Low
- 8.400
- Amount
- 3.11M
- EV/EBITDA, TTM
- -2.24
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
AI analysis of Picard Medical Inc (PMI)
buyPicard Medical Inc is a good buy right now due to significant recent revenue growth and improving financial metrics. The stock closed at $8.80, with a remarkable 5-day change of +174.14%, indicating strong momentum. Additionally, the gross margin improved to 20.9% in Q2 2026 from negative margins a year earlier, showcasing effective cost management. However, the main risk is the ongoing net loss of approximately $5.7 million in Q2 2026, which reflects the company's need for continued operational improvements.
バリュエーション指標
イベントタイムライン
ニュース
9.508-24NASDAQ.COMPicard Medical Reports Strong Q2 Results, Shares Surge 40%
8.507-27GlobenewswirePicard Medical Unveils Next-Gen Artificial Heart System
8.507-27NewsfilterPicard Medical Unveils Emperor Drive System at IEEE EMBC 2026
8.507-27seekingalphaPicard Medical Secures Compliance Period Until 2027 from NYSE American
8.507-22NASDAQ.COMPicard Medical Approves 1-for-50 Reverse Stock Split
PMI FAQ — answered by Alphio AI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber. It operates in the Healthcare sector.
Picard Medical Inc is a good buy right now due to significant recent revenue growth and improving financial metrics. The stock closed at $8.80, with a remarkable 5-day change of +174.14%, indicating strong momentum. Additionally, the gross margin improved to 20.9% in Q2 2026 from negative margins a year earlier, showcasing effective cost management. However, the main risk is the ongoing net loss of approximately $5.7 million in Q2 2026, which reflects the company's need for continued operational improvements.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。